BofA raised the firm’s price target on Amentum (AMTM) to $30 from $27 and keeps a Neutral rating on the shares. The firm cites improved investor sentiment and the company’s market premium for its nuclear exposure for the target increase. Amentum benefits from a nuclear premium, the analyst tells investors in a research note. Heading into 2026, BofA expects defense and intelligence funding to remain strong, while civilian agency funding “remains a question mark.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMTM:
- Amentum selected as prime contractor on $3.5B DTRA contract
- Amentum wins $120M Defense Information Systems Agency computer processing award
- Amentum price target raised to $35 from $30 at BTIG
- DoE selects TVA, Holtetc to support early deployments of small modular reactors
- Amentum price target raised to $40 from $35 at Cantor Fitzgerald